Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Consensus PT from Analysts
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target […]
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target […]
